All Articles

Politecnico di Milano launches a bold plan to tackle Europe's innovation gap and foster global talent, blending deep tech with a deep sense of social duty.

AlarmForce founder Joel Matlin is back, betting on a new wearable called ZippyBack to disrupt the booming sports memorabilia market. Is it a game-changer?

A new AI platform is creating digital replicas of every clinical trial site, promising to slash drug development timelines and costs. Here's how.

A new Pennsylvania casino is not just filling a vacant mall; it's using advanced tech from Konami to redefine the guest experience and boost local economy.

Beyond AI headlines lies a critical skills gap. An innovative partnership in India is building the cloud workforce that will power healthcare's digital future.

A South Korean firm's breakthrough in thermal control for industrial magnets could solve a costly problem, promising a new era of efficiency and durability.

A German biotech's methodical approach and key partnerships are de-risking the path for a new PAH therapy, offering a model for stable value creation.

Equiti Group partners with TraderEvolution, signaling a major upgrade in trading tech. What does this mean for traders and the competitive fintech landscape?

The launch of new, lower-cost drugs for osteoporosis and cancer could transform patient care and ease the strain on strained healthcare systems.

Pershing Square's latest share buyback is more than routine; it's a bold statement on valuation and a core tenet of Bill Ackman's capital strategy.

Flush with cash from vaccine sales and a savvy asset sale, Bavarian Nordic's DKK 500M buy-back reveals a mature strategy. Is it strength or a pause?

Accord Healthcare's launch of denosumab biosimilars promises to lower costs for critical osteoporosis and cancer treatments, fueling a wider revolution.

Prop trading leader FTMO's acquisition of brokerage giant OANDA signals a major industry shift, creating a unified ecosystem for traders.

A UK regulatory filing has peeled back the curtain on Qualcomm's big bet on Alphawave IP, revealing the high-stakes battle for the tech that will power AI medicine.

After a decade of delays, a Malaysian mega-mall is reborn. Hextar World's radical blend of entertainment, culture, and community aims to disrupt retail.

Millions with osteoporosis and cancer may soon access vital, lower-cost bone treatments as a wave of new biosimilars hits the market, promising major savings.

A UK filing reveals Park West's complex trades in Qualcomm. What do these options plays signal about the chip giant's acquisition and its AI ambitions?

Accord Healthcare's launch of two new bone-health biosimilars promises to expand access for millions and ease financial strain on European health systems.

Beyond the awards, a South Korean tech giant is reshaping public services and defining the enterprise AI playbook for the entire Asia-Pacific region.

Autonomous AI now executes campaigns and even buys products for consumers. As the CMO becomes a 'Chief Profit Officer,' who is accountable for the machines?